Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06733363 · ClinicalTrials.gov registry record · Phase 2
A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer
A Phase 2 study of Stage 0a Bladder Cancer AJCC v8 and Non-Muscle Invasive Bladder Carcinoma, sponsored by Roswell Park Cancer Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 344
- Enrollment target
- 1
- Study location
NCT06733363: Recruiting Phase 2 study of Stage 0a Bladder Cancer AJCC v8 and Non-Muscle Invasive Bladder Carcinoma, sponsored by Roswell Park Cancer Institute.
NCT06733363 is a Phase 2 study of Stage 0a Bladder Cancer AJCC v8 and Non-Muscle Invasive Bladder Carcinoma that is actively recruiting participants, run by Roswell Park Cancer Institute. The registered enrollment target is 344 participants, above the 197-participant average among 7 other Stage 0a Bladder Cancer AJCC v8 trials with a reported enrollment target (75% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06733363, a Phase 2 study of Stage 0a Bladder Cancer AJCC v8 and Non-Muscle Invasive Bladder Carcinoma, is actively recruiting participants, sponsored by Roswell Park Cancer Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 344 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial is being done to develop and test a healthy eating program to reduce cancer recurrence (cancer that has come back after a period of improvement) and/or progression (cancer that is growing, spreading, or getting worse) in patients with non-muscle invasive bladder cancer (NMIBC). Researchers want to better understand how incorporating more cruciferous vegetables in the diet may reduce the risk of cancer recurrence or progression in men and women who were diagnosed with early-stage bladder cancer and compare whether extending the program can further improve bladder cancer outcomes. POW-R Health is a behavioral dietary intervention designed to modestly increase cruciferous vegetable (cruciferae) intake in patients. Cruciferous vegetables, such as cabbage, kale and broccoli, arugula, contain phytochemicals known as isothiocyanates (ITCs). Dietary ITCs exert potent anticancer activities against bladder cancer and can be rapidly metabolized, delivered to the bladder, and concentrated in the urine. Participating in the healthy eating program may reduce bladder cancer recurrence or progression in NMIBC survivors.
Primary Outcome
Levels with be measured using high performance liquid chromatography-based cyclocondensation assay
Conditions Studied
Interventions
- BEHAVIORAL Behavioral Dietary Intervention
- BEHAVIORAL Telephone- Based Intervention
Study Locations (1)
New York
- Roswell Park Comprehensive Cancer Center - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 344 participants |
| Start Date | 2026-01-13 |
| Est. Completion | 2029-02-28 |
| Phase | Phase 2 |
What NCT06733363 shows while recruiting
NCT06733363 is an interventional study that assigns participants to a tested intervention. The registered 344 participants enrollment target is mid-sized for trials with a published cap, above the 197-participant average among 7 other Stage 0a Bladder Cancer AJCC v8 trials with a reported enrollment target (75% higher).
The record links to 5 conditions, with Stage 0a Bladder Cancer AJCC v8 appearing as the primary indexed condition, and to 2 interventions - of which Behavioral Dietary Intervention is the first listed.
NCT06733363 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06733363 about?
NCT06733363 is a clinical study titled "A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer". This phase II trial is being done to develop and test a healthy eating program to reduce cancer recurrence (cancer that has come back after a period of improvement) and/or progression (cancer that is growing, spreading, or getting worse) in patients with non-muscle invasive bladder cancer (NMIBC). R...
What is the current status of trial NCT06733363?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 344 participants. The study started on 2026-01-13. Estimated completion is 2029-02-28.
What conditions does trial NCT06733363 study?
This clinical trial studies the following conditions: Stage 0a Bladder Cancer AJCC v8, Non-Muscle Invasive Bladder Carcinoma, Recurrent Non-Muscle Invasive Bladder Carcinoma, Recurrent Bladder Carcinoma, Stage 1 Bladder Cancer AJCC v8.
What interventions are being tested in trial NCT06733363?
The interventions under investigation include: Behavioral Dietary Intervention (BEHAVIORAL), Telephone- Based Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT06733363?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06733363 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage 0a Bladder Cancer AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
ACTIVE NOT RECRUITING · Phase 2
-
In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial
RECRUITING · Phase 1
-
Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study
RECRUITING
-
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
RECRUITING · Phase 3
-
Home-Based Physical Activity Program With Digital App Versus Health Education Group for Improving Physical Activity Among Patients With Non-muscle Invasive Bladder Cancer, The EMPOWER Trial
RECRUITING · NA
-
IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07179380 · 344 participants · Phase 3
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- NCT07304024 · 344 participants · Phase 1
A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound
- NCT03972657 · 345 participants · Phase 1
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
- NCT05107674 · 345 participants · Phase 1
A Study of NX-1607 in Adults With Advanced Malignancies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI